galcanezumab
Sign in to saveAlso known as LY-2951742, LY2951742, clone III
Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for the treatment of cluster headaches.
Key facts
- Drug.type
- mab
- Drug.image
- Emgality.jpg
- Drug.mab_type
- mab
- Drug.source
- zu
- Drug.target
- CALCA, CALCB
- Drug.tradename
- Emgality
- Drug.MedlinePlus
- a618063
- Drug.DailyMedID
- Galcanezumab
- Drug.routes_of_administration
- Subcutaneous
- Drug.class
- Calcitonin gene-related peptide receptor antagonist
- Drug.ATC_prefix
- N02
- Drug.ATC_suffix
- CD02
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 1578199-75-3
- Drug.PubChemSubstance
- 346930785
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 3 more facts
- World Health Organisation international non-proprietary name
- galcanezumab
- defined daily dose
- 4
- subject has role
- monoclonal antibody
Sources (3)
via Wikidata · CC0
~5 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Mechanism of action
- History
- Clinical trials
- Society and culture
- Economics
- Legal status
- References
Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for the treatment of cluster headaches.
A substance called calcitonin gene-related peptide (CGRP) has been shown to be involved in the development of migraine by widening blood vessels in the brain. Galcanezumab is a monoclonal antibody (a type of protein) designed to attach to and block CGRP, thereby helping blood vessels to return to their normal size. This will stop the symptoms of migraine. Galcanezumab is generally delivered through self-injections. Common side effects include injection site reactions such as pain or redness. Other side effects may include hypersensitivity reactions.
Excerpted from Wikipedia’s “galcanezumab” article, available under the CC BY-SA 4.0 licence.